The Role of Cytokines and Molecular Pathways in Lung Fibrosis Following SARS-CoV-2 Infection

Mikhail Petrov^*
*Correspondence: Mikhail Petrov, Department of Infectious Diseases, University of Oxford, Wellington Square, Oxford OX1 2JD, UK, Email:

Introduction

Severe Acute Respiratory Syndrome Coronavirus 2 the causative agent of COVID-19, has become a global health crisis since its emergence in late 2019. While the primary presentation of COVID-19 is respiratory in nature, a subset of patients develops complications such as lung fibrosis, leading to long-term morbidity and mortality. Understanding the molecular mechanisms underlying the development of lung fibrosis post-SARS-CoV-2 infection is crucial for devising effective therapeutic strategies. This article explores the role of cytokines and molecular pathways in driving lung fibrosis following SARS-CoV-2 infection [1,2].

Lung fibrosis, characterized by excessive deposition of extracellular matrix proteins such as collagen, arises as a consequence of dysregulated wound healing and tissue repair processes. In the context of COVID-19, the pathogenesis of lung fibrosis is multifactorial, involving both direct viralinduced injury and dysregulated host immune responses. Following SARSCoV- 2 infection, alveolar epithelial cells and pulmonary endothelial cells undergo damage, triggering an inflammatory cascade mediated by various cytokines and chemokines. Cytokines play a central role in orchestrating the immune response to viral infections and are implicated in the pathogenesis of lung fibrosis post-SARS-CoV-2 infection. Pro-inflammatory cytokines such as interleukin-6 tumor necrosis factor-alpha and interleukin-1β are elevated in COVID-19 patients with severe disease and are associated with poor clinical outcomes. These cytokines promote fibroblast activation, ECM deposition, and myofibroblast differentiation, driving the development of lung fibrosis.

Description

Several molecular pathways contribute to the development and progression of lung fibrosis following SARS-CoV-2 infection. The transforming growth factor-beta pathway is a key mediator of fibrotic responses, promoting ECM synthesis and inhibiting ECM degradation. Dysregulated TGF-β signaling leads to excessive collagen deposition and fibroblast proliferation, contributing to the fibrotic phenotype observed in COVID-19 patients. Additionally, the Janus kinase-signal transducer and activator of transcription pathway implicated in cytokine signaling, plays a role in fibroblast activation and ECM remodeling. Immune dysregulation, characterized by aberrant cytokine production and dysregulated immune cell responses, contributes to fibroblast activation and ECM deposition in COVID-19-associated lung fibrosis. Alveolar macrophages, recruited to the site of injury, produce pro-fibrotic cytokines and chemokines, perpetuating the fibrotic cascade. Moreover, dysregulated T cell responses, including skewed T helper cell subsets and impaired regulatory T cell function, further exacerbate tissue damage and fibrosis [3,4].

Understanding the molecular mechanisms driving lung fibrosis following SARS-CoV-2 infection is essential for the development of targeted therapies. Targeting cytokines such as IL-6 and TNF-α using monoclonal antibodies or small molecule inhibitors represents a potential therapeutic strategy to mitigate inflammation and fibrosis in COVID-19 patients. Additionally, targeting key molecular pathways involved in fibrosis, including the TGF-β and JAK-STAT pathways, holds promise for preventing or attenuating lung fibrosis post- SARS-CoV-2 infection [5].

Conclusion

Lung fibrosis represents a significant complication of severe COVID-19, contributing to long-term morbidity and mortality. Cytokines and molecular pathways play crucial roles in driving the fibrotic response following SARSCoV- 2 infection, highlighting potential therapeutic targets for intervention. Further research into the intricate interplay between cytokines, immune dysregulation, and fibroblast activation is warranted to develop effective therapeutic strategies for mitigating lung fibrosis in COVID-19 patients.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Mineo, Giangaspare, F. Ciccarese, C. Modolon and Maria Paola Landini, et al. "Post-ARDS pulmonary fibrosis in patients with H1N1 pneumonia: Role of follow-up CT." Radiol Med 117 (2012): 185.

Google Scholar, Crossref, Indexed at

2. Shieh, Jiunn-Min, Hui-Yun Tseng, Fang Jung and Shih-Hsing Yang, et al. "Elevation of IL-6 and IL-33 levels in serum associated with lung fibrosis and skeletal muscle wasting in a bleomycin-induced lung injury mouse model." Mediat Inflamm 2019 (2019).

Google Scholar, Crossref, Indexed at                    

3. She, Yi Xin, Qing Yang Yu and Xiao Xiao Tang. "Role of interleukins in the pathogenesis of pulmonary fibrosis." Cell Death Discov 7 (2021): 52.

Google Scholar, Crossref Indexed at

4. Ayaub, Ehab A., Anisha Dubey, Jewel Imani and Fernando Botelho, et al. "Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis." Sci Rep 7 (2017): 13281.

Google Scholar, Crossref Indexed at

5. Adegunsoye, Ayodeji and Jay Balachandran. "Inflammatory response mechanisms exacerbating hypoxemia in coexistent pulmonary fibrosis and sleep apnea." Mediat Inflamm (2015).

Google Scholar, Crossref, Indexed at